|View printer-friendly version|
“The field of neuroscience is rapidly changing and evolving,” said
Among the posters the Charles River team will present are innovative tools and applications for research targeting Huntington’s, Alzheimer’s, Parkinson’s, Multiple Sclerosis, Duchenne Muscular Dystrophy, and other neurological disorders. Noteworthy examples include:
A collaboration with the
University of Eastern Finlandand Kuopio University Hospitalon the use of dynamic PET imaging. (Dynamic PET Imaging with Arterial Input Function of Lipopolysaccharide-Induced Neuroinflammation in Rat)
- A collaboration with Cure Huntington's Disease Initiative (CHDI) on the utilization of Rho kinase inhibitors for Huntington’s disease therapeutics. (Progress Towards Potent, Selective and Brain Penetrant Rho Kinase Inhibitors Suitable for a Proof-of-Concept Study in HD Models)
- The study of altered nerve cell function in Huntington’s disease models. (Investigation of Corticostriatal Synaptic Transmission and Cerebellar Purkinje Neuron Firing in the R6/2 Mouse Model of Huntington’s Disease by Using Multi-Electrode Arrays)
Additionally, the Charles River team, in conjunction with
A full schedule of Charles River’s activities during Neuroscience 2016 is available on our website, and reprints of each poster are available in Charles River’s booth (#1619) during the conference. Additionally, CNS experts are available for meetings with those interested in discussing neuroscience research and drug discovery. Throughout the conference, Charles River will be providing live updates on the Eureka Blog, including reviews of scientific sessions and input on the research being presented.
About the Society for Neuroscience
About Charles River
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.
Charles River Laboratories International, Inc.
Amy Cianciaruso, 781-222-6168
Corporate Vice President, Public Relations